ライフサイエンスコーパス: oesophageal cancer

1 , ongoing controversies, and future needs in oesophageal cancer.

2 ompared with surgery alone for patients with oesophageal cancer.

3 tasis precludes long-term survival in distal oesophageal cancer.

4 lignant dysphagia in patients with incurable oesophageal cancer.

5 sociation was seen with risk or survival for oesophageal cancer.

6 dence for surgery in the treatment of gastro-oesophageal cancer.

7 with placebo in previously treated advanced oesophageal cancer.

8 the development of Barrett's metaplasia and oesophageal cancer.

9 SEMS effectively palliate inoperable oesophageal cancer.

10 n is the mainstay of treatment for localised oesophageal cancer.

11 d epigenetically or in regulatory regions in oesophageal cancer.

12 tify a gene that may be involved in familial oesophageal cancer.

13 ry as standard treatment of locally advanced oesophageal cancer.

14 The odds of being a case of oesophageal cancer, adjusted for smoking status, were si

15 t of early gastrointestinal cancers, such as oesophageal cancer, and lung cancer.

16 nut are known risk factors for many oral and oesophageal cancers, and their use is highly prevalent i

17 S are placed in all patients with inoperable oesophageal cancer, as in our study, rather than those f

18 For lung and oesophageal cancer, benefit was confined to adenocarcino

19 ixed, wax-embedded sections from a series of oesophageal cancer cases previously shown to contain MMP

20 rative effects in colonic mucosa and in some oesophageal cancer cell lines.

21 circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing concurrent c

22 the recently published chemoradiotherapy for oesophageal cancer followed by surgery study trial showe

23 isease locus [previously termed the "tylosis oesophageal cancer gene' (TOC) locus] has been mapped to

24 urgical resection for stage III or IV distal oesophageal cancer in 1987-2010 with follow-up until 201

25 EMS placement as sole therapy for inoperable oesophageal cancer in a resource-limited setting.

26 ce for an increase in the risk of gastric or oesophageal cancer in bisphosphonate users and one findi

27 an appropriate technology for palliation of oesophageal cancer in resource-limited settings.

28 ost all patients who underwent resection for oesophageal cancer in Sweden in 1987-2010.

29 ermal dysplasia type III) is associated with oesophageal cancer in three families: two large pedigree

30 e of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not impro

31 rt a small but significant increased risk of oesophageal cancer in women prescribed bisphosphonates a

32 Therapies for inoperable oesophageal cancer include chemoradiotherapy and placeme

33 Endoscopically diagnosed oesophageal cancer increased by 32 % per decade, but gas

34 Oesophageal cancer is a clinically challenging disease t

35 Oesophageal cancer is one of the 10 leading causes of ca

36 c role of lymphadenectomy during surgery for oesophageal cancer is questioned.

37 a small but significantly increased risk of oesophageal cancer linked to duration of bisphosphonate

38 of Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires pre

39 eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumou

40 er cardiovascular and circulatory disorders, oesophageal cancer, preterm birth complications, congeni

41 carce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and n

42 the promoter is hypermethylated in sporadic oesophageal cancer samples: this may constitute the 'sec

43 ciated with the early onset of squamous cell oesophageal cancer (SCOC) in three families.

44 rapy cannot be recommended for patients with oesophageal cancer suitable for definitive CRT.

45 Lymphadenectomy during oesophageal cancer surgery is a safe procedure in the sh

46 are the cause of the inherited cutaneous and oesophageal cancer-susceptibility syndrome tylosis with

47 Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative trea

48 ls in a collection of DNA samples taken from oesophageal cancer tissues.

49 erma (Tylosis) associated with squamous cell oesophageal cancer (TOC) has been mapped to chromosome 1

50 lotype analyses have mapped the tylosis with oesophageal cancer (TOC) locus to a 42.5 kb region on ch

51 ned entirely within the 42.5 kb tylosis with oesophageal cancer (TOC) minimal region.

52 on mutations in iRHOM2 underlie Tylosis with oesophageal cancer (TOC), characterized by palmoplantar

53 cancer-susceptibility syndrome tylosis with oesophageal cancer (TOC), suggesting a role for this pro

54 prospectively gathered on all patients with oesophageal cancer treated with SEMS between Jan 1, 1999

55 ncluded patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) thro

56 Thus, patients with distal oesophageal cancer with coeliac node metastasis seem to